• 1
    Vaezi MF. ‘Refractory GERD’: acid, nonacid, or not GERD? Am J Gastroenterol 2004; 99: 98990.
    Direct Link:
  • 2
    Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000; 95: 307180.
    Direct Link:
  • 3
    Johnson DA, Lauritsen K, Junghard O, Levine D. Evaluation of symptoms is an unreliable predictor of relapse of erosive esophagitis in patients receiving maintenance PPI therapy (abstract). Gastroenterology 2003; 124: A-540 (no. T1646).
  • 4
    Fass R, Thomas S, Traxler B, Sostek M. Patient reported outcome of heartburn improvement: doubling the proton pump inhibitor (PPI) dose in patient who failed standard dose PPI vs. switching to a different PPI (abstract). Gastroenterology 2004; 146: A-37 (no. 326).
  • 5
    Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy – a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14: 1595603.
  • 6
    DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastro-oesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med 1995; 155: 216573.
  • 7
    Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completed relieved with PPIs. Am J Gastroenterol 2003; 98: 19404.
    Direct Link:
  • 8
    Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of 56 treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 11924.
  • 9
    Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs study. JCOM 2000; 7: 2934.
  • 10
    Fass R. Distinct phenotypic presentations of gastro-oesophageal reflux disease: a new view of the natural history. Dig Dis 2004; 22: 1007.
  • 11
    Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996; 10: 54755.
  • 12
    Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 9749.
  • 13
    Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastro-oesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 13329.
    Direct Link:
  • 14
    Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive refluxdisease. Clin Gastroenterol Hepatol 2004; 2: 65664.
  • 15
    Faybush EM, Green C, Malagon IB, Fass R. A high overlap in esophageal acid exposure between the gastro-oesophageal reflux disease (GERD) groups supports distinct phenotypic presentations rather than the spectrum continuum model (abstract). Gastroenterology 2005; 128: A384, M1748.
  • 16
    Clouse RE, Richter JE, Heading RC, Janssens J, Wilson JA. Functional esophageal disorders. In: Drossman, DA, Corazziari, E, Talley, NJ, Thompson, WG, Whitehead, WE, The Rome II Multinational Working Teams, eds. Rome II The Functional Gastrointestinal Disorders, 2nd edn. Lawrence, KS, USA: Allen Press Inc., 2000: 275.
  • 17
    Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD) – acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 53745.
  • 18
    Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux – the ‘sensitive oesophagus’. Gut 1997; 40: 58790.
  • 19
    Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastro-oesophageal reflux disease. Arch Intern Med 2000; 160: 18039.
  • 20
    Bardhan KD, Hawkey CJ, Long RG, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Pharmacol Ther 1995; 9: 14551.
  • 21
    Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996; 91: 174957.
  • 22
    Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001; 15: 22731.
  • 23
    Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared to omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 65665.
    Direct Link:
  • 24
    Fass R, Sampliner RE. Barrett's oesophagus: optimal strategies for prevention and treatment. Drugs 2003; 63: 55564.
  • 25
    Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002; 51: 88592.
  • 26
    Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's oesophagus. Am J Gastroenterol 1994; 89: 98991.
  • 27
    Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's oesophagus. Am J Gastroenterol 1998; 93: 7116.
    Direct Link:
  • 28
    Fass R, Sampliner RE, Malagon IB, et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000; 14: 597602.
  • 29
    El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's oesophagus. Am J Gastroenterol 2004; 99: 187783.
    Direct Link:
  • 30
    Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998; 12: 8937.
  • 31
    Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's oesophagus. Am J Gastroenterol 1994; 89: 18448.
  • 32
    Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's oesophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44: 7005.
  • 33
    Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999; 49: 4634.
  • 34
    The Gallup Organization. Gallup Study of Consumers’ Use of Stomach Relief Products. Princeton, NJ: The Gallup Organization, 2000.
  • 35
    Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996; 91: 15328.
  • 36
    Verdu EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 53943.
  • 37
    Vigneri S, Termini R, Savarino V, Pace F. Review article: Is Helicobacter pylori status relevant to the management of GORD? Aliment Pharmacol Ther 2000; 14: 3142.
  • 38
    Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 116.
  • 39
    Delhotal-Landes B, Cournot A, Vermerie N, Dellatolas F, Benoit M, Flouvat B. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991; 3: 31520.
  • 40
    Dammann HG, Fuchs W, Richter G, Brukhardt F, Wolf N, Wlater TA. Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997; 11: 35964.
  • 41
    Leite L, Lambrecht N, Sachs G, Castell DO, Langerström P. Is omeprazole resistance due to mutations of cysteine 813 or 822 in the acid pump (abstract). Gastroenterology 1995; 108: A147.
  • 42
    Robinson M. Review article: The pharmacodynamics and pharmacokinetics of proton pump inhibitors – overview and clinical implications. Aliment Pharmacol Ther 2004; 20: 110.
  • 43
    Caraco Y, Wilkinson GR, Wood AJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996; 60: 396404.
  • 44
    Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastro-oesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72: 45360.
  • 45
    Kawamura M, Ohara S, Koike T, et al. The effect of lansoprazole on erosive reflux esophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17: 96573.
  • 46
    Egan LJ, Myhre GM, Mays DC, Dierkhising RA, Kammer PP, Murray JA. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther 2003; 17: 152118.
  • 47
    Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 7637.
    Direct Link:
  • 48
    Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98: 54550.
    Direct Link:
  • 49
    Fouad YM, Katz PO, Castell DO. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999; 13: 146771.
  • 50
    Nzeako UC, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 2002; 16: 130916.
  • 51
    Orr WC, Harnish MJ. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 2003; 17: 15538.
  • 52
    Vaezi MF. Duodenogastroesopahgeal reflux. In: Castell, DO, Richter, JE, eds. The Oesophagus, 4th edn. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2004: 43450.
  • 53
    Stipa F, Stein HJ, Feussner H, Kraemer S, Siewert JR. Assessment of non-acid esophageal reflux: comparison between long-term reflux aspiration test and fiberoptic bilirubin monitoring. Dis Oesophagus 1997; 10: 248.
  • 54
    Vaezi MF, Richter JE. Role of acid and duodenogastro-oesophageal reflux in gastro-oesophageal reflux disease. Gastroenterology 1996; 111: 11929.
  • 55
    Netzer P, Gut A, Brundler R, Gaia C, Halter F, Inauen W. Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. Aliment Pharmacol Ther 2001; 15: 137584.
  • 56
    Marshall RE, Anggiansah A, Manifold DK, Owen WA, Owen WJ. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. Gut 1998; 43: 6036.
  • 57
    Tack J, Koek G, Demedts I, Sifrim D, Janssens J. Gastro-oesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's oesophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99: 9818.
    Direct Link:
  • 58
    Vela M, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastro-oesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120: 1599606.
  • 59
    Shay S, Sifrim D, Tutuian R, Zhang X, Vela M, Castell DO. Multichannel intraluminal impedance (MII) in the evaluation of patients with persistent GERD symptoms despite proton pump inhibitors (PPI): a multicenter study (abstract). Gastroenterology 2003; 124: A-537 (no. T1633).
  • 60
    Frazzoni M, De Micheli E, Zentilin P, Savarino V. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004; 20: 818.
  • 61
    Fass R, Ofman JJ. Gastro-oesophageal reflux disease – should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 19019.
  • 62
    Hobson AR, Matthews P, Furlong P, Aziz Q. The role of esophageal afferent pathway sensitivity in non-erosive reflux disease (abstract). Gastroenterology 2004; 126: A-18 (no. 128).
  • 63
    Castell DO, Murray JA, Tutuian R, Orlando RC, Arnold R. Review article: The pathophysiology of gastro-oesophageal reflux disease – oesophageal manifestations. Aliment Pharmacol Ther 2004; 20: 1425.
  • 64
    Buckles DC, Sarosiek I, McMillin C, McCallum RW. Delayed gastric emptying in gastro-oesophageal reflux disease: reassessment with new methods and symptomatic correlations. Am J Med Sci 2004; 327: 14.
  • 65
    McCallum RW, Berkowitz DM, Lerner E. Gastric emptying in patients with gastro-oesophageal reflux. Gastroenterology 1981; 80: 28591.
  • 66
    Kudara N, Chiba T, Orii S, Suzuki K. Gastric emptying of patients with persistent reflux symptoms and erosive esophagitis under PPI therapy (abstract). Neurogastroenterol Motil 2004; 16: 654 (no. 23).
  • 67
    Sotoudehmanesh R, Ali Asgari A, Ansari R, Nouraie M. Endoscopic findings in end-stage renal disease. Endoscopy 2003; 35: 5025.
  • 68
    Cucchiara S, Minella R, Campanozzi A, et al. Effects of omeprazole on mechanisms of gastro-oesophageal reflux in childhood. Dig Dis Sci 1997; 42: 2939.
  • 69
    Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 1617.
  • 70
    Loftus CG, Harewood GC, Romero Y, Cameron AJ, Murray JA. Declining diagnostic utility of upper endoscopy in patients with gastro-oesophageal reflux disease (abstract). Gastrointest Endosc 2002; 55: AB89 (no. 459).
  • 71
    Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996; 110: 198296.
  • 72
    Fass R, Ofman JJ, Pulliam G, Lembo A. Persistent symptoms of heartburn in patients on standard doses of proton pump inhibitors (PPI) are not due to acid reflux in most patients (abstract). Gastroenterology 1999; 116: A160 (no. G0694).
  • 73
    Vaezi MF, Richter JE, Stasney ER, et al. A randomized, double-blind, placebo-controlled study of acid suppression for the treatment of suspected laryngopharyngeal reflux (abstract). Gastroenterology 2004; 126: A22 (no. 160).
  • 74
    Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas PJ. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003; 98: 7409.
    Direct Link:
  • 75
    Wong W, Bautista J, Dekel R, et al. Feasibility and tolerability of transnasal/per-oral placement of the wireless pH capsule vs. traditional 24-h oesophageal pH monitoring – a randomized trial. Aliment Pharmacol Ther 2005; 21: 15563.
  • 76
    Bechi P, Pucciani F, Baldini F, et al. Long-term ambulatory enterogastric reflux monitoring. Validation of a new fiberoptic technique. Dig Dis Sci 1993; 38: 1297306.
  • 77
    Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 90312.
  • 78
    Bate CM, Booth SN, Crowe JP, Hepworth-Jones B, Taylor MD, Richardson PDI. Does 40 mg omeprazole daily offer additional benefit over 20 mg dial in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther 1993; 7: 5017.
  • 79
    Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397402.
  • 80
    Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 15039.
  • 81
    Clouse RE. Psychotropic medications for the treatment of functional gastrointestinal disorders. Clin Perspect Gastroenterol 1999; 2: 34856.
  • 82
    Varia I, Logue E, O'Connor C, et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 2000; 140: 36772.
  • 83
    Prakash C, Clouse RE. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 1999; 44: 23739.
  • 84
    So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastro-oesophageal reflux treated by laparoscopic fundoplication. Surgery 1998; 124: 2832.
  • 85
    Chuttani R, Sud R, Sachdev G, et al. A novel endoscopic full-thickness plicator for the treatment of GERD: a pilot study. Gastrointest Endosc 2003; 58: 7706.
  • 86
    Triadafilopoulos G, Dibaise JK, Nostrant TT, et al. Radiofrequency energy delivery to the gastroesophageal function for the treatment of GERD. Gastrointest Endosc 2001; 53: 4.
  • 87
    Feretis C, Benakis P, Dimopoulos C, et al. Endoscopic implantation of Plexiglas (PMMA) microspheres for the treatment of GERD. Gastrointest Endosc 2001; 53: 4236.
  • 88
    Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TO, Huang B, Pencyla JL. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001; 96: 308998.
    Direct Link: